Novartis' Partnership Ambitions
Novartis' rather public search for a co-promotion partner for tegaserod (Zelmac) has ended up garnering the Swiss firm a bigger partner than it might have expected-and a partner that badly needed a drug to sell--Bristol-Myers. But Novartis is doing more with this co-promotion than simply finding a co-promtoion partner and some quids--it's advertising its willingness to go outside of the company's walls for the firepower it needs and its belief in the necessity of more global partnerships--or perhaps one really big one.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.